BioSpace News Archive

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, reported financial and corporate results for the first quarter ended March 31, 2020.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its financial results for the first quarter 2020 and provided a corporate update.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, reported financial results from the first quarter ending March 31, 2020 and provided an update on corporate activities.

Danaher Corporation announced that it has closed concurrent offerings of 9,509,203 shares of common stock at a price to the public of $163.00 per share and 1,717,500 shares of 5.00% Series B Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.

Cortexyme, Inc., a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced financial results for the first quarter 2020 and provided an update on its business.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announced that it will report financial results for the first quarter ended March 31, 2020 on Thursday, May 14, 2020 after the market close.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock.

Mylan and Gilead Sciences sign global collaboration agreement for the commercialization of remdesivir in 127 low- and middle-income countries

Affera, Inc., a private medical device company focused on innovative cardiac arrhythmia treatment solutions, announced that its platform was featured prominently in scientific sessions at the Heart Rhythm Society 2020 meeting held online May 6-9.

Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that it plans to make an offering of $500 million of its common stock in a registered underwritten offering.